Cardiovascular implications of proteinuria: an indicator of chronic kidney disease (original) (raw)

• Sarnak, M. J. et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154–2169 (2003).
  Article PubMed Google Scholar
• Vassalotti, J. A., Stevens, L. A. & Levey, A. S. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am. J. Kidney Dis. 50, 169–180 (2007).
  Article CAS PubMed Google Scholar
• Garg, A. X., Kiberd, B. A., Clark, W. F., Haynes, R. B. & Clase, C. M. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 61, 2165–2175 (2002).
  Article PubMed Google Scholar
• Segura, J., Campo, C. & Ruilope, L. M. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int. Suppl. 92, S45–S49 (2004).
  Article Google Scholar
• Weir, M. R. Microalbuminuria and cardiovascular disease. Clin. J. Am. Soc. Nephrol. 2, 581–590 (2007).
  Article PubMed Google Scholar
• Boulware, L. E., Jaar, B. G., Tarver-Carr, M. E., Brancati, F. L. & Powe, N. R. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 290, 3101–3114 (2003).
  Article CAS PubMed Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (2 Suppl. 1), S1–S266 (2002).
• Kashif, W., Siddiqi, N., Dincer, A. P., Dincer, H. E. & Hirsch, S. Proteinuria: how to evaluate an important finding. Cleve. Clin. J. Med. 70, 535–537, 541–544, 546–547 (2003).
  Article PubMed Google Scholar
• Tonelli, M. et al. Chronic kidney disease and mortality risk: a systematic review. J. Am. Soc. Nephrol. 17, 2034–2047 (2006).
  Article PubMed Google Scholar
• Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B. & Smith, D. H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 164, 659–663 (2004).
  Article PubMed Google Scholar
• Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
  Article CAS PubMed Google Scholar
• Agarwal, R., Bunaye, Z., Bekele, D. M. & Light, R. P. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am. J. Nephrol. 28, 569–575 (2008).
  Article PubMed Google Scholar
• de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921–927 (2004).
  Article CAS PubMed Google Scholar
• Maschio, G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939–945 (1996).
  Article CAS PubMed Google Scholar
• [No authors listed.] Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349, 1857–1863 (1997).
• Ordoñez, J. D., Hiatt, R. A., Killebrew, E. J. & Fireman, B. H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 44, 638–642 (1993).
  Article PubMed Google Scholar
• Liu, J. E., Robbins, D. C., Palmieri, V., Bella, J. N., Roman, M. J., Fabsitz, R., Howard, B. V., Welty, T. K., Lee, E. T., Devereux, R. B. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J. Am. Coll. Cardiol. 41, 2022–2028 (2003).
  Article CAS PubMed Google Scholar
• Miettinen, H., Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27, 2033–2039 (1996).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation 118, 1577–1584 (2008).
  Article PubMed PubMed Central Google Scholar
• Eddy, A. A. Proteinuria and interstitial injury. Nephrol. Dial. Transplant. 19, 277–281 (2004).
  Article PubMed Google Scholar
• Abbate, M., Zoja, C. & Remuzzi, G. How does proteinuria cause progressive renal damage? J. Am. Soc. Nephrol. 17, 2974–2984 (2006).
  Article CAS PubMed Google Scholar
• Fort, J. Chronic renal failure: a cardiovascular risk factor. Kidney Int. 68, S25–S29 (2005).
  Article Google Scholar
• Ridao, N. et al. Prevalence of hypertension in renal disease. Nephrol. Dial. Transplant. 16 (Suppl. 1), 70–73 (2001).
  Article PubMed Google Scholar
• Inoue, T. et al. Proteinuria as a significant determinant of hypertension in a normotensive screened cohort in Okinawa, Japan. Hypertens. Res. 29, 687–693 (2006).
  Article CAS PubMed Google Scholar
• Agarwal, R. & Andersen, M. J. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 46, 514–520 (2005).
  Article CAS PubMed Google Scholar
• Ohya, Y. et al. Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort. Am. J. Kidney Dis. 47, 790–797 (2006).
  Article CAS PubMed Google Scholar
• Brenner, B. M. et al. RENAAL Study. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
  Article CAS PubMed Google Scholar
• Lewis, E. J. et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
  Article CAS PubMed Google Scholar
• So, W. Y. et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension 44, 294–299 (2004).
  Article CAS PubMed Google Scholar
• Marre, M. et al. DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328, 495 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• ONTARGET Investigators et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547–1559 (2008).
• Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547–553 (2008).
  Article CAS PubMed Google Scholar
• Tylicki, L. et al. Triple pharmacological blockade of the renin–angiotensin–aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am. J. Kidney Dis. 52, 486–493 (2008).
  Article CAS PubMed Google Scholar
• Barraclough, K. A. et al. Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure. Nephrol. Dial. Transplant. 23, 3199–3205 (2008).
  Article PubMed PubMed Central Google Scholar
• Haydar, A. A. et al. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol. Dial. Transplant. 19, 2307–2312 (2004).
  Article PubMed Google Scholar
• Olson, J. C., Edmundowicz, D., Becker, D. J., Kuller, L. H. & Orchard, T. J. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 49, 1571–1578 (2000).
  Article CAS PubMed Google Scholar
• Wagenknecht, L. E. et al. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 50, 861–866 (2001).
  Article CAS PubMed Google Scholar
• Mehrotra, R. et al. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 66, 2022–2031 (2004).
  Article PubMed Google Scholar
• Kasiske, B. L. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis. 32 (Suppl. 3), S142–S156 (1998).
  Article CAS PubMed Google Scholar
• Lee, T. M., Su, S. F. & Tsai, C. H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40, 67–73 (2002).
  Article CAS PubMed Google Scholar
• Lee, T. M., Lin, M. S., Tsai, C. H. & Chang, N. C. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int. 68, 779–787 (2005).
  Article CAS PubMed Google Scholar
• Bianchi, S., Bigazzi, R., Caiazza, A. & Campese, V. M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 41, 565–570 (2003).
  Article CAS PubMed Google Scholar
• Hommel, E. et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35, 447–451 (1992).
  Article CAS PubMed Google Scholar
• Thomas, M. E. et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int. 44, 1124–1129 (1993).
  Article CAS PubMed Google Scholar
• Rabelink, A. J., Hené, R. J., Erkelens, D. W., Joles, J. A. & Koomans, H. A. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 2, 1335–1338 (1988).
  Article CAS PubMed Google Scholar
• Strippoli, G. F. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645–651 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Agarwal, R. Statin induced proteinuria: renal injury or renoprotection? J. Am. Soc. Nephrol. 15, 2502–2503 (2004).
  Article PubMed Google Scholar
• Brunzell, J. D. et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31, 811–822 (2008).
  Article CAS PubMed Google Scholar
• Myers, G. L. et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 110, 545–549 (2004).
  Article CAS Google Scholar
• Caglar, K. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 70, 781–787 (2006).
  Article CAS PubMed Google Scholar
• Yilmaz, M. I. et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J. Am. Soc. Nephrol. 19, 388–395 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Stehouwer, C. D. et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51, 1157–1165 (2002).
  Article CAS PubMed Google Scholar
• Jaffa, A. A. et al. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 52, 1215–1221 (2003).
  Article CAS PubMed Google Scholar
• Takebayashi, K., Matsumoto, S., Aso, Y. & Inukai, T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese type 2 diabetic patients. J. Diabetes Complications 20, 98–104 (2006).
  Article PubMed Google Scholar
• Hirano, T., Kashiwazaki, K., Moritomo, Y., Nagano, S. & Adachi, M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 36, 11–18 (1997).
  Article CAS PubMed Google Scholar
• Zimmermann, J. et al. Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy. Clin. Nephrol. 46, 230–236 (1996).
  CAS PubMed Google Scholar
• Blum, M. S. et al. Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines. Am. J. Physiol. 273, H286–;H294 (1997).
  CAS PubMed Google Scholar
• Michel, C. C. Transport of macromolecules through microvascular walls. Cardiovasc. Res. 32, 644–653 (1996).
  Article CAS PubMed Google Scholar
• Vogel, S. M. et al. Evidence of transcellular permeability pathway in microvessels. Microvasc. Res. 61, 87–101 (2001).
  Article CAS PubMed Google Scholar
• Stocker, R. & Keaney, J. F. Jr Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004).
  Article CAS PubMed Google Scholar
• Parving, H. H. et al. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. Diabetologia 39, 1590–1597 (1996).
  Article CAS PubMed Google Scholar
• Paisley, K. E. et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 63, 624–633 (2003).
  Article PubMed Google Scholar
• Wever, R. M., Lüscher, T. F., Cosentino, F. & Rabelink, T. J. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 97, 108–12 (1998).
  Article CAS PubMed Google Scholar
• Stroes, E. S., Koomans, H. A., de Bruin, T. W. & Rabelink, T. J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 346, 467–471 (1995).
  Article CAS PubMed Google Scholar
• Vuong, T. D. et al. Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects. Kidney Int. 55, 1005–1010 (1999).
  Article CAS PubMed Google Scholar
• Kougias, P. et al. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med. Sci. Monit. 12, RA5–RA16 (2006).
  CAS PubMed Google Scholar
• Zhu, X., Wu, S., Dahut, W. L. & Parikh, C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49, 186–193 (2007).
  Article CAS PubMed Google Scholar
• Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Stokes, M. B., Erazo, M. C. & D'Agati, V. D. Glomerular disease related to anti-VEGF therapy. Kidney Int. 74, 1487–1491 (2008).
  Article CAS PubMed Google Scholar
• Anavekar, N. S. et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int. Suppl 92, S50–S55 (2004).
  Article Google Scholar
• Halbesma, N. et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J. Am. Soc. Nephrol. 17, 2582–2590 (2006).
  Article PubMed Google Scholar
• Borch-Johnsen, K., Andersen, P. K. & Deckert, T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28, 590–596 (1985).
  Article CAS PubMed Google Scholar
• Cardoso, C. R. & Salles, G. F. Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients. Braz. J. Med. Biol. Res. 41, 674–680 (2008).
  Article CAS PubMed Google Scholar
• Kannel, W. B., Stampfer, M. J., Castelli, W. P. & Verter, J. The prognostic significance of proteinuria: the Framingham study. Am. Heart J. 108, 1347–1352 (1984).
  Article CAS PubMed Google Scholar
• Astor, B. C., Hallan, S. I., Miller, E. R. 3rd, Yeung, E. & Coresh, J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am. J. Epidemiol. 167, 1226–1234 (2008).
  Article PubMed Google Scholar
• Hillege, H. L. et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106, 1777–1782 (2002).
  Article CAS PubMed Google Scholar
• Howard, B. V. et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 99, 2389–2395 (1999).
  Article CAS PubMed Google Scholar
• Xu, J. et al. Association of albuminuria with all-cause and cardiovascular disease mortality in diabetes: the Strong Heart Study. Br. J. Diabetes Vasc. Dis. 5, 334–340 (2005).
  Article CAS Google Scholar
• Yuyun, M. F. et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am. J. Epidemiol. 159, 284–293 (2004).
  Article PubMed Google Scholar
• Wang, Z. & Hoy, W. E. Albuminuria and incident coronary heart disease in Australian Aboriginal people. Kidney Int. 68, 1289–1293 (2005).
  Article PubMed Google Scholar
• Valmadrid, C. T., Klein, R., Moss, S. E. & Klein, B. E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Intern. Med. 160, 1093–1100 (2000).
  Article CAS PubMed Google Scholar
• Culleton, B. F., Larson, M. G., Parfrey, P. S., Kannel, W. B. & Levy, D. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am. J. Med. 109, 1–8 (2000).
  Article CAS PubMed Google Scholar
• Irie, F. et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 69, 1264–1271 (2006).
  Article CAS PubMed Google Scholar
• Madison, J. R. et al. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up. Arch. Int. Med. 166, 884–889 (2006).
  Article Google Scholar
• Nakayama, M. et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. Nephrol. Dial. Transplant. 22, 1910–1915 (2007).
  Article PubMed Google Scholar
• MacKinnon, M. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am. J. Kidney Dis. 48, 8–20 (2006).
  Article CAS PubMed Google Scholar
• Bakris, G. L., Weir, M. R., DeQuattro, V. & McMahon, F. G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 54, 1283–1289 (1998).
  Article CAS PubMed Google Scholar
• Hou, F. F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889–1898 (2007).
  Article CAS PubMed Google Scholar
• Aranda, P. et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am. J. Kidney Dis. 46, 1074–1079 (2005).
  Article CAS PubMed Google Scholar
• Bianchi, S., Bigazzi, R. & Campese, V. M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116–2123 (2006).
  Article CAS PubMed Google Scholar
• Schjoedt, K. J. et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 68, 2829–2836 (2005).
  Article CAS PubMed Google Scholar
• Chrysostomou, A., Pedagogos, E., MacGregor, L. & Becker, G. J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 1, 256–262 (2006).
  Article CAS PubMed Google Scholar
• Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433–2446 (2008).
  Article CAS PubMed Google Scholar
• Ansquer, J. C. et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am. J. Kidney Dis. 51, 904–913 (2008).
  Article CAS PubMed Google Scholar
• Bakris, G. L. & Weir, M. R. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am. J. Hypertens. 9, 200S–206S (1996).
  Article CAS PubMed Google Scholar
• Bakris, G. L. & Smith, A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann. Intern. Med. 125, 201–204 (1996).
  Article CAS PubMed Google Scholar
• Heeg, J. E., de Jong, P. E., van der Hem, G. K. & de Zeeuw, D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 36, 272–279 (1989).
  Article CAS PubMed Google Scholar
• Buter, H., Hemmelder, M. H., Navis, G., de Jong, P. E. & de Zeeuw, D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant. 13, 1682–1685 (1998).
  Article CAS PubMed Google Scholar
• Rosenberg, M. E., Swanson, J. E., Thomas, B. L. & Hostetter, T. H. Glomerular and hormonal responses to dietary protein intake in human renal disease. Am. J. Physiol. 253, F1083–F1090 (1987).
  CAS PubMed Google Scholar
• Pan, Y., Guo, L. L. & Jin, H. M. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 88, 660–666 (2008).
  Article CAS PubMed Google Scholar
• Menon, V. et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am. J. Kidney Dis. 53, 208–217 (2009).
  Article CAS PubMed Google Scholar